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Interaction Between the Trace 
Amine-Associated Receptor 1 and 
the Dopamine D2 Receptor Controls 
Cocaine’s Neurochemical Actions
Aman Asif-Malik1, Marius C. Hoener  2 & Juan J. Canales3
Recent evidence suggests that the trace amine-associated receptor 1 (TAAR1) plays a pivotal role 
in the regulation of dopamine (DA) transmission and cocaine’s actions. However, the underlying 
mechanisms through which TAAR1 activation mediates these effects have not yet been elucidated. 
Here, we used fast-scan cyclic voltammetry to measure DA dynamics and explore such mechanisms. 
We show, first, that the full TAAR1 agonist, RO5256390, dose-dependently blocked cocaine-induced 
inhibition of DA clearance in slices of the nucleus accumbens. Second, subthreshold inhibition of PKA 
or PKC phosphorylation did not prevent TAAR1 suppression of cocaine effects whereas subeffective 
doses of the DA D2 receptor antagonist, L-741,626, rescued cocaine’s ability to produce changes in 
DA uptake in the presence of full TAAR1 activation, thus indicating that TAAR1 modulation of cocaine 
effects requires simultaneous DA D2 receptor activation. Predictably, inhibition of glycogen synthase 
kinase-3 (GSK-3), which results from activation of D2/TAAR1 heterodimers, fully reproduced the 
inhibitory effects of TAAR1 activation on cocaine-induced changes in DA transmission. Collectively, the 
present observations reveal that the ability of TAAR1 to regulate cocaine effects is linked to cooperative 
interactions with D2 autoreceptors and associated downstream molecular targets converging on GSK-3 
and suggest a new mechanism to disrupt cocaine neurochemical actions.
The trace amine-associated receptor 1 (TAAR1) is a G protein-coupled receptor that is responsive to trace amines 
(TAs), the major catecholamines and synthetic compounds structurally related to TAs, including amphetamine 
and its numerous analogues, triggering accumulation of cAMP via adenylyl cyclase activation1,2. TAAR1 mRNA 
and protein expression is enriched in the limbic system and in brain areas associated with the major aminer-
gic pathways, including ascending dopaminergic and serotonergic projections3–5. The distribution of TAAR1 
is predominantly intracellular, with diffuse expression within the perikaryon and axonal processes and sparse 
membrane-bound localization at synaptic sites1,4, thus being uniquely positioned to regulate aminergic activity. 
Previous in vitro and in vivo evidence suggests that TAAR1 stimulation exerts inhibitory control over monoam-
inergic neurotransmission. Indeed, transgenic mice lacking Taar1 (Taar1−/− mice) exhibited a markedly elevated 
discharge rate of dopamine (DA) and serotonin (5-HT) neurons in the midbrain5,6, and increased DA transmis-
sion in the nucleus accumbens (NAc)7. Conversely, selective TAAR1 activation with the full agonist, RO5166017, 
reduced the firing frequency of DA neurons in the midbrain6, whereas the selective TAAR1 antagonist, EPPTB, 
elevated it8. This remarkable ability of TAAR1 to regulate DA transmission has spurred a wealth of research into 
TAAR1 as a target for pharmacological intervention in neuropsychiatry, including addictive disorders9.
It is well documented that TAAR1 has the ability to modulate the neurochemical and behavioural effects 
of psychomotor stimulants. Initial observations showed that the partial agonist, RO5203648, decreased 
cocaine-stimulated locomotor activity and cocaine self-administration10. Partial and full TAAR1 activation sim-
ilarly prevented the lowering effects of cocaine on brain reward thresholds and the reinforcing and motivational 
effects of cocaine in a self-administration paradigm11,12. Notably, TAAR1 activation blocked cocaine relapse in 
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models of spontaneous renewal, drug-primed and cue-induced reinstatement12,13. Although previous in vitro 
research has shown that partial TAAR1 activation reduced cocaine-induced DA overflow in the NAc12, the signal-
ling pathways and molecular interactions involved in its modulation of cocaine-induced changes in DA uptake, 
which underlie the reinforcing and euphoric effects of cocaine14,15, are unknown. Delineating such pathways is 
crucial to develop and optimize TAAR1-based treatments for addiction and other disorders associated with DA 
dysfunction.
TAAR1’s cellular distribution allows this receptor to regulate aminergic transmission by way of interactions 
with transporter sites, presynaptic autoreceptors and associated intracellular signalling cascades9. TAAR1 stimu-
lation triggers accumulation of cAMP via Gαs-adenylyl cyclase activation which can, in turn, promote PKA and 
PKC phosphorylation1–3,16, and also activates a G protein-independent, β-arrestin2-dependent pathway involv-
ing protein kinase B (AKT)/glycogen synthase kinase-3 (GSK-3)17, which is modulated by DA D2 receptors18. 
Although such widespread molecular interactions complicate the identification of the mechanisms responsible 
for TAAR1’s capacity to regulate cocaine’s neurochemical actions, here we used in vitro fast-scan cyclic voltamme-
try to monitor changes in electrically evoked DA transmission produced by cocaine and aimed to characterize the 
underlying substrates linked to TAAR1’s ability to regulate the neurochemical actions of cocaine.
Methods
Tissue preparation. Brain slices from 58 male Lister Hooded rats were used for this study. The experi-
ments were carried out under institutional ethics approval (AWERB Sub-committee, University of Leicester) and 
appropriate project and personal license authority granted by the UK Home Office under the Animals (Scientific 
Procedures) Act 1986. Prior to use, animals were housed on a 12 h light/dark cycle with ad libitum access to food 
and water. On the day of the experiment, a rat was anaesthetized with isofluorane and culled via a schedule 1 pro-
cedure (under the Animals Scientific Procedures Act 1986, Amendment Regulations 2012). The brain was rapidly 
removed and placed in a tube containing pre-carboxygenated (i.e. bubbled with 95% O2 and 5% CO2), ice-cold, 
sodium-free slicing artificial cerebrospinal fluid (S.aCSF), so as to prevent synaptic transmission during slicing, 
consisting of 250 mM sucrose (Merck Group, Germany), 2.5 mM KCl (Sigma-Aldrich, UK), 11 mM d-glucose 
(Sigma-Aldrich, UK), 1.2 mM NaH2PO4 (Sigma-Aldrich, UK), 25 mM NaHCO3 (Sigma-Aldrich, UK), 0.4 mM 
l-ascorbic acid (Sigma-Aldrich, UK), 0.1 mM CaCl2 (Sigma-Aldrich, UK), and 4 mM MgCl2 (Thermo Fisher 
Scientific, Belgium), and adjusted to pH 7.4. The brain was then sectioned in ice-cold carboxygenated S.aCSF on 
a Vibratome 1000 Classic vibrating microtome (The Vibratome Company, MO, USA). Coronal slices (400 µM) of 
the striatum containing the NAc were maintained at room temperature in continuously carboxygenated exper-
imental aCSF (E.aCSF), which consisted of 126 mM NaCl, 2.5 mM KCl, 11 mM d-glucose, 1.2 mM NaH2PO4, 
25 mM NaHCO3, 0.4 mM l-ascorbic acid, 2.4 mM CaCl2, 1.2 mM MgCl2 and adjusted to pH 7.4. Slices were 
allowed to recover for at least 30 min at room temperature before use. The various experimental manipulations 
started 5–10 min after transfer to the FSCV slice chamber (see below and Fig. 1) to allow slices to equilibrate in 
warmed aCSF.
FSCV electrodes. Recording electrodes were manufactured as described previously19. A single carbon fiber 
(7 µm in diameter; Goodfellow, Cambridge Ltd.) was aspirated into a borosilicate glass capillary (100 mm length, 
1/0.58 mm OD/ID; World Precision Instruments, FL, USA). The capillary was then pulled to a fine tip using a 
vertical needle puller (PE-21, Narishige, Japan) and the exposed carbon fibre was cut, using a scalpel, to 100 µm in 
length. A silver conductive paint (Coating Silver Print II, GC Electronics, USA) coated piece of wire was inserted 
into the capillary, secured with a gold pin (Newark, IL, USA) and heat shrink-wrapped to the capillary (FP-301, 
3 M). Each electrode was tested to ensure a suitable background (non-Faradaic) current profile by applying the 
Figure 1. Diagrammatic representation of the protocol used for each experimental drug condition. A 350 μA 
stimulation was passed every 3 m (red arrows), at 5 s passed the start of the 3 min file (set at 50 Hz with 10 pulses 
and a 1 ms pulse width), which is presented as each coloured rectangle. Drugs were perfused 3 min before the 
following stimulation so as to observe drug effects during the corresponding stimulation. Two electrically-
stimulated responses were used to calculate an average effect for each condition. X corresponds to any of the 
agonists/antagonists used in these experiments.
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voltage waveform at 60 Hz. Each good electrode was then cycled at 60 Hz for a maximum of 30 min from −0.4 to 
1.3 V and back (versus an Ag/AgCl reference) at a ramp of 400 V/s and application frequency of 60 Hz until stable. 
Stability was determined when the baseline recording showed a drift of no more than 2 nA over 30 s. Once stable, 
electrodes were cycled from −0.4 to 1.3 V and back at 400 V/s at a frequency of 10 Hz until the drift was again min-
imal. Reference electrodes were manufactured with a piece of silver wire coated in KCl (Ag/AgCl) and attached to a 
silver pin (Newark, IL, USA). Bipolar stimulating electrodes were purchased directly (FHC, ME, USA).
FSCV equipment. The FSCV setup was custom built, consisting of a slice chamber, stimulating, recording 
and reference electrodes connected to a computer and amplifier. The recording and reference electrodes were 
connected to a potentiostat and head stage circuit (ChemClamp, Dagan Instruments USA) and a computer run-
ning Demon Voltammetry Software (Wakeforest Innovations, NC, USA). Two data acquisition cards (NI-DAQ; 
PCI-6711 and PCI-6052e; National Instruments, Austin, TX) were used for interfacing Demon Voltammetry with 
a Chem-Clamp potentiostat (Dagan Corporation; Minneapolis, MN) for voltammetric recordings. The NI-DAQ 
cards contain multiple on-board high-speed clocks, and several 16 bit analogue outputs/inputs suitable for gen-
erating potential sweeps and acquiring voltammograms at high rates (>100 kHz) while performing electrical 
stimulations for evoking DA release. NI-DAQ cards were connected to the potentiostat via specialized breakout 
boxes created locally from 2 NI-DAQ CB-68LPR screw terminals20. The recording electrode potential was linearly 
scanned at a rate of 400 V/s as a triangular waveform from −0.4 V to 1.3 V and back to −0.4 V vs the reference 
electrode. Cyclic voltammograms were recorded at the recording electrode every 100 ms by means of the voltam-
meter (Dagan Instruments, USA). At this waveform, DA oxidizes at ~ 0.6 V and reduces at ~−0.2 V.
FSCV recordings. For recordings, a slice was placed in the FSCV slice chamber, held in place with a 
purpose-built grid and superfused with continuously carboxygenated E.aCSF at a flow rate of 1.4 ml/m heated 
with a purpose-built peltier to 32–33°C. Waste E.aCSF was aspirated at the same flow rate from the other 
end of the slice chamber. Flow and aspiration rate was controlled with a Minipulse peristaltic pump (Gilson, 
Bedfordshire, UK). The recording electrode was positioned ~75 µm below the surface of the slice in the NAc. 
DA release was electrically evoked at 50 Hz every 3 min by a 1 ms, ten-pulse stimulation (monophasic, 300 µA) 
using the stimulating electrode placed 100–200 µm from the recording electrode within the NAc. Current pulses 
were generated by the acquisition software and applied via an ISo-Flex stimulus isolator (A.M.P. Instruments, 
Jerusalem, Israel). Voltage waveforms (10 Hz) were applied to electrodes using Demon software and the resulting 
changes to current were recorded and analysed. The recording electrode generates a characteristic background 
signal that was subtracted to yield the Faradaic current caused by oxidation and reduction of DA. DA was con-
firmed in each recording by observation of the cyclic voltammogram (noting the position of oxidation and reduc-
tion peaks; for e.g. Fig. 2c) and colour plots permitted the visualization of release dynamics over time (Fig. 2a,b).
Drugs were applied by superfusion at the same time as the recording was initiated. Slices were randomly assigned 
to the different trials. Trials consisted of 9, 15 or 21 min runs with an electrical stimulation administered every 3 min 
of either no drug, 1 or 10 µM cocaine (Sigma, UK), 2 or 5 µM of the full TAAR1 agonist, RO5256390 (Hoffmann-La 
Roche Ltd., Switzerland), followed by 6 min of co-application of RO5256390 (2 or 5 µM) with 10 µM cocaine (see 
Fig. 1). The effects of cocaine on DA outflow was found to return to a stable pre-stimulation level within 3 min and 
concentrations of all other drugs used in this study were chosen on the basis of no effect on DA transmission when 
perfused alone. This enabled us to take two reliable peak and tau measures for each condition within each slice and 
calculate the average prior to gathering the total average for each condition from all slices.
The lower concentration of cocaine tested in this experiment (1 μM) produced small increases in release but no 
changes in DA clearance (results not shown) and the higher cocaine concentration demonstrated consistently robust 
effects on DA overflow. Thus, we decided to use the higher concentration of cocaine throughout the rest of the study 
to investigate the mechanisms through which TAAR1 modulates cocaine-induced alterations in DA uptake.
The following drugs were also used: phorbol 12-myristate 13-acetate (PMA) [protein kinase C (PKC) activa-
tor; 0.1 or 0.3 µM;21,22] (Sigma-Aldrich, UK), Go 6983 (PKC inhibitor; 0.1, 2 or 10 µM21; (Sigma-Aldrich, UK), 
3′, 5′- cyclic adenosine monophosphate sodium salt (cAMP) [protein kinase A (PKA) activator; 3 or 10 µM23] 
(Santa Cruz Biotechnology, TX, USA), KT 5720 [PKA inhibitor; 2 nM, 20 nM or 0.1 µM24,25] (Sigma-Aldrich, 
UK), sumanirole (D2 receptor agonist; 0.1 or 0.3 µM26; Sigma-Aldrich, UK), L-741,626 (D2 receptor antagonist; 
3 nM, 30 nM or 0.1 µM26; Santa Cruz Biotechnology, CA, USA) and SB216763 [GSK-3 inhibitor; 0.1 µM or 1 µM27; 
(Cell guidance systems, Cambridge, UK)]. Concentrations for all compounds were selected on the basis of empir-
ical data involving neurochemical or electrophysiological actions in slice preparations (as referenced above) and 
adjusted based on their effects in our own preparation, but always to lower doses than those previously reported. 
Only concentrations of drugs that had an effect on cocaine-induced DA transmission but no significant effect 
on DA clearance in their own right were used for ease of interpretation. Each slice was perfused with only one 
drug in the absence and presence of cocaine. In each condition, two electrically stimulated responses, over the 
time course of six minutes were taken from each slice. In order to ensure there was no effect on either peak or tau 
measures from cumulative stimulation within the entire length of the longest experiment (21 min), slices were 
stimulated every 3 min in the absence of any drug and no effect on either peak or tau between the first and last 
stimulation was confirmed, thus enabling us to confidently base our findings on drug treatment.
Background subtracted cyclic voltammograms were obtained by subtracting the current obtained at the point 
before stimulation of every experiment, before drugs were superfused into the slice chamber. The peak oxidation 
current (nA) for DA in each voltammogram has been deemed an appropriate measure of DA release and tau an 
adequate measure of DA reuptake. Tau is a measure of exponential decay from peak to baseline20. The n value 
represents number of slices.
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Statistical Analysis. All assessments are reported in relation to percent from baseline. Recorded current 
(nA) vs time data were extracted from Demon Voltammetry Software and exported to a tab delimited file, com-
patible with Microsoft Excel. Percentage increases or decreases from baseline of DA release (i.e. peak) and DA 
reuptake (i.e. tau) in the presence of any treatment was analysed. Data were analysed by one-way ANOVA to 
compare the effects of the various manipulations across groups followed by post-hoc Fisher’s Least Significant 
Test comparisons. Additionally, we conducted a t-test to compare the effects of specific drugs against their own 
baseline where applicable. Statistical significance was set at α = 0.05 for all experiments. All statistical analyses 
were performed using StatView 5.0 (SAS Institute, NC, USA).
Results
Effects of cocaine on DA transmission. Cocaine (10 μM) was superfused onto NAc brain slices for a total 
of 9 min. Stimulation was applied at the beginning of every third min allowing a measure of basal DA transmis-
sion (i.e. the electrically stimulated response in the absence of any drug) and two measures of cocaine-induced 
changes in DA transmission. The average effects (peak and tau) of two cocaine-induced changes in DA transmis-
sion were compared to the basal values, and percentage increases/decreases of either peak or tau in the presence 
of a drug were analysed. The background-subtracted cyclic voltammogram identified the detected analyte as DA 
(Fig. 2c) and colour plots represented the voltammetric currents (encoded in colour in the z-axis) plotted against 
the applied potential (y-axis) and time (x-axis) (Fig. 2b,c).
DA peak response was unaffected by cocaine in comparison to the average baseline peak response (Fig. 2d; 
−4.42 ± 10.09%, n = 19), whereas tau was significantly increased in the presence of 10 μM cocaine (Fig. 2e; 
258.50 ± 44.20%; F(1,18) = 9.27, p = 0.007, n = 19).
Figure 2. RO5256390 reduces cocaine-induced increases in DA transmission in slices of rat NAc. 
Representative traces demonstrate the effect of cocaine (Co; 10 μM) perfusion on electrically-stimulated (at 
350 μA; 10 pulses set at 50 Hz with a 1 ms pulse width) DA outflow in comparison to baseline in raw current 
values (nA) (a). The colour plots represent the voltammetric currents (encoded in colour in the z-axis) plotted 
against time (x-axis) (b). An example of the background-subtracted cyclic voltammogram, which identified the 
detected analyte as DA (c). Application of 10 μM Co resulted in a significant decrease in DA uptake which was 
significantly attenuated by both 2 μM and 5 μM RO5256390 but had no effect on DA release (d,e). (*p < 0.05, 
**p < 0.01 vs baseline; #p < 0.05, ##p < 0.01 vs cocaine values; n = 7–19).
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Effects of TAAR1 activation on DA transmission. To investigate whether TAAR1 activation affected 
DA transmission when applied alone, NAc slices were superfused with two concentrations of RO5256390 (2 μM 
or 5 μM). The average of two stimulus-induced responses was calculated and percentage deviation from base-
line (i.e. stimulus-induced DA transmission in the presence of no drug) responses in each slice was analysed by 
t-test. Both the low (mean peak 0.40 ± 11.28%, mean tau −4.35 ± 12.35% deviation from baseline) and the high 
(−0.11 ± 4.20%, mean tau 15.31 ± 16.84% concentrations of RO5256390 were without effect by themselves on 
either peak DA or tau (Fig. 2d,e; n = 10–13).
TAAR1 modulation of cocaine-induced inhibition of DA clearance. To investigate TAAR1’s effect 
on cocaine-stimulated DA overflow, brain slices were perfused with cocaine (10 μM) and RO5256390 (2 μM or 
5 μM) in combination. The mean peak and tau deviations from baseline for 10 μM cocaine in the presence of 2 μM 
RO5256390 were 36.93 ± 26.07% and 52.86 ± 43.04% respectively; and those for 10 μM cocaine in the presence 
of 5 μM RO5256390 were 3.36 ± 9.48% and −13.59 ± 17.24% respectively. ANOVA revealed a significant main 
effect of treatment for RO5256390 (Fig. 2d,e; F(4,52) = 11.76, p < 0.001, n = 15) and post-hoc analysis showed that 
cocaine-induced changes in tau were dose-dependently attenuated by the full TAAR1 agonist (p < 0.01).
Effects of selective PKA activators and inhibitors on cocaine-induced changes in DA transmis-
sion. We targeted individual pathways that are known to be involved in TAAR1’s downstream signalling cas-
cades9 to assess their impact on cocaine’s effects and their influence on TAAR1’s modulation of cocaine’s effects. 
The PKA activator (cAMP) and the inhibitor (KT 5720) were superfused alone and in the presence of cocaine 
so as to ensure effects observed were due to the activator and inhibitor in their own right. All concentrations of 
KT 5720 were found to significantly increase DA release in comparison to baseline (Fig. 3a; 36.34 ± 16.67% peak 
deviation, 28.25 ± 5.27% tau deviation; F(1,4) = 15.08, p = 0.018, n = 5; 20 nM and 39.39 ± 9.69% peak deviation, 
Figure 3. Effects of PKA inhibition and activation on cocaine-induced changes in DA transmission. Co-
application of 10 μM cocaine (Co) with either a PKA activator (cAMP) or an inhibitor (KT 5720; KT) resulted 
in a significant increase in DA release (a). KT also caused a significant increase in peak DA in comparison 
to baseline values when perfused alone (a). Superfusing cocaine with either 10 μM cAMP or 0.1 μM KT 
significantly attenuated cocaine-induced increases in tau (b). Perfusion of the lowest concentration of KT, which 
had no effect on DA clearance in its own right, in the presence of both 5 μM RO5256390 and 10 μM cocaine, 
had no effect on RO5256390’s ability to attenuate cocaine-induced increases in tau (d). (*p < 0.05, **p < 0.01 vs 
baseline; #p < 0.05, ##p < 0.01 vs cocaine values; n = 5–19).
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−1.45 ± 10.69% tau deviation F(1,4) = 7.39, p = 0.042, n = 5; 100 nM; see below for 2 nM KT 5720). In addition, by 
activating or inhibiting the PKA pathway, we significantly altered cocaine-induced changes in DA transmission 
(Fig. 3a; F(10,77) = 2.28, p = 0.021, n = 29). Both cAMP (45.42 ± 23.08% and 36.76 ± 22.08% for 3 μM cAMP and 
10 μM cAMP respectively) and KT 5720 (68.36 ± 19.64% and 50.27 ± 13.64% for 20 nM and 100 nM KT 5720 
respectively) significantly potentiated the effect of cocaine on peak DA. Post-hoc analysis showed that this effect 
was greater in the presence of the lower concentrations of both the activator and inhibitor (3 μM cAMP and 
20 nM KT 5720; p < 0.01). In addition, both the activator and the inhibitor dose-dependently attenuated cocaine’s 
effect on tau (Fig. 3b; F(10,77) = 7.11, p < 0.001, n = 29). The mean tau deviations from baseline for 10 μM cocaine 
in the presence of 3 and 10 μM cAMP was 248.01 ± 82.25% and 21.87 ± 21.16% respectively; and those for 10 μM 
cocaine in the presence of 20 and 100 nM KT 5720 were 137.76 ± 50.01 and 7.29 ± 15.13% respectively.
In order to establish whether the observed effects of inhibiting the PKA pathway played a role in TAAR1’s 
ability to regulate cocaine-induced changes in DA transmission, we superfused KT 5720 (2 nM) together with 
both RO5256390 and cocaine. This concentration of KT 5720 was established as ineffective on cocaine’s ability to 
increase tau (241.43 ± 79.83% deviation from baseline) but was found to significantly increase DA release when 
perfused alone in comparison with baseline responses (Fig. 3a; 25.34 ± 10.49%; F(1,12) = 6.47, p = 0.026, n = 13). 
Therefore, in order to ascertain whether or not PKA played a role in TAAR1’s ability to alter cocaine effect on DA 
transport, we used this low concentration of KT 5720. We found that in the presence of 2 nM KT 5720, TAAR1’s 
ability to modulate cocaine’s effect on DA reuptake was unaffected (Fig. 3d; 28.66 ± 16.73%; F(6,65) = 10.93, 
p < 0.001, n = 7). In addition, perfusion of both 2 nM KT 5720 and 5 μM RO5256390 had no effect on tau in the 
absence of cocaine (2.80 ± 7.26% deviation from baseline), although they did induce a similar significant increase 
in peak as observed with 2 nM KT 5720 alone (32.32 + 19.33% deviation from baseline).
Effects of selective PKC activators and inhibitors on cocaine-induced changes in DA transmis-
sion. We then aimed to establish any possible effects of modulating the PKC pathway in a similar fashion 
by superfusing an activator (PMA) and an inhibitor (Go 6983) of PKC, alone and in the presence of cocaine. 
The selective PKC activator PMA was superfused at two different concentrations, 100 nM (15.09 ± 11.20% 
deviation from baseline peak and −12.60 ± 11.68% deviation from baseline tau) and 300 nM (42.87 ± 16.58% 
deviation from baseline peak and 14.03 ± 9.73% deviation from baseline tau) and the inhibitor Go 6983 was 
superfused at 100 nM (13.74 ± 8.99% deviation from baseline peak and 32.48 ± 30.52% deviation from base-
line tau), 2 μM (27.36 ± 16.03% deviation from baseline peak and 2.91 ± 5.00% deviation from baseline tau) and 
10 μM (2.35 ± 10.12% deviation from baseline peak and 2.75 ± 11.64% deviation from baseline tau). A significant 
effect of treatment was found on both cocaine-induced peak DA (Fig. 4a; F(10,73) = 2.73, p = 0.007, n = 29) and tau 
(Fig. 4b; F(10,73) = 7.53, p < 0.001, n = 29) and post-hoc analyses revealed a significant increase in cocaine-induced 
peak DA following perfusion of 2 μM Go 6983 (58.48 ± 31.60%) and 100 nM PMA (92.70 ± 21.86%) (p < 0.01). 
Further, a dose-dependent reduction of tau on co-application of cocaine with both the activator and the inhibitor 
was observed (p < 0.01). The mean tau deviations from baseline for 10 μM cocaine in the presence of 100 nM and 
300 nM PMA was 136.60 ± 66.12% and 8.52 ± 18.51% respectively; and those for 10 μM cocaine in the presence 
of 100 nM, 2 μM and 10 μM Go 6983 were 270.52 ± 44.62%, 48.57 ± 7.92 and 18.47 ± 13.91% respectively.
We then superfused the selective PKC inhibitor Go 6983 at the inert concentration of 0.1 μM with RO5256390 
and cocaine to establish whether the PKC pathway played a role in TAAR1’s ability to modulate cocaine-induced 
DA changes in uptake. In the presence of Go 6983, RO5256390 was still able to completely block cocaine’s 
effect on tau (Fig. 4d; −0.59 ± 25.02%; F(6,63) = 11.01, p < 0.001, n = 6) and thus the PKC inhibitor did not affect 
TAAR1’s ability to modulate cocaine-induced changes in DA clearance. A significant increase in DA peak did 
occur, however, on co-application of this inert concentration of Go 6983 and RO5256390 (Fig. 4c; 45.20 ± 33.82%; 
F(1,4) = 10.989, p = 0.030, n = 5), indicating that although this concentration of the PKC inhibitor had no effect on 
cocaine-induced increases in tau, it was physiologically active.
Modulation of DA clearance by TAAR1 is inhibited by DA D2 receptor antagonism. To investi-
gate whether D2 receptors play a significant role in TAAR1’s ability to modulate cocaine-induced DA overflow, 
we perfused the highly selective and potent D2 receptor agonist, sumanirole, at two different concentrations (0.1 
and 0.3 μM) both alone at 100 nM (19.90 ± 18.82% deviation from baseline peak and 8.56 ± 18.43% deviation 
from baseline tau) and 300 nM (−3.05 ± 16.31% deviation from baseline peak and −0.92 ± 10.77% deviation 
from baseline tau) and in the presence of cocaine. Sumanirole, with an EC50 between 17–75 nM28, has more than 
200-fold selectivity for the D2 receptor subtype in comparison to other DA receptor subtypes. ANOVA revealed 
a significant effect of treatment on cocaine-induced increases in tau (Fig. 5b; F(8,67) = 7.89, p < 0.001, n = 10). 
Sumanirole exposure produced a significant, dose-dependent reduction in tau on co-application with cocaine 
(61.92 ± 25.54% and −17.09 ± 6.08% at the lower and higher concentration respectively; p < 0.01). No effect of 
sumanirole treatment was found on cocaine’s effect on peak DA (Fig. 5a; 10.88 ± 23.94% and −7.32 ± 16.59% 
with 100 nM and 300 nM respectively; n = 10).
We then sought to further assess the role of D2 receptors on cocaine-induced increases in tau by using the selec-
tive D2 receptor antagonist, L-741,626. A significant, dose-dependent increase in DA release on co-application of 
cocaine with both concentrations of L-741,626 was observed (68.34 ± 13.31% and 235.17 ± 84.38% respectively), 
as shown by ANOVA and post-hoc analysis (Fig. 5a; F(8,67) = 4.63, p < 0.01, n = 14). In addition, post-hoc analyses 
also showed that at the higher concentration, L-741,626 significantly increased cocaine-induced changes in tau 
(Fig. 5b; 523.33 ± 176.67%; p < 0.01).
We went on to evaluate the effects of the D2 receptor antagonist, L-741,626, on TAAR1’s ability to modulate 
DA transmission by superfusing 10 μM cocaine with both 30 nM L-741,626 and 5 μM RO5256390. We selected 
the 30 nM of L-741,626 because the previous experiment indicated that this dose did not affect tau following 
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single application or in combination with cocaine, although it still was able to produce changes in DA release 
in comparison to basal values (Fig. 5c; 122.61 ± 48.66%; F(1,15) = 8.461, p < 0.011, n = 16). A similar increase in 
tau on co-application of L-741,626 with RO5256390 and cocaine, in comparison to cocaine alone, was observed 
(Fig. 5d; 288.47 ± 84.06%; F(6,69) = 9.754, p < 0.001, n = 7). Therefore, at concentrations that were devoid of effects 
on tau following single application, L-741,626 blocked RO5256390’s ability to inhibit cocaine-induced increases 
in tau and thus the ability of TAAR1 to modulate cocaine’s effects on DA clearance. Interestingly, the opposite was 
observed in peak, where RO5256390 inhibited the peak increase induced by L-741,626 (Fig. 5c,d; 6.24 ± 8.21%).
Cocaine-induced increases in tau are blocked by GSK-3 inhibition. In order to further confirm 
whether the TAAR1/D2R interactions are crucial for TAAR1 to regulate cocaine-induced alterations in DA trans-
mission, we inhibited the GSK-3 pathway using the selective GSK-3 inhibitor, SB216763. Since GSK-3 is acti-
vated by D2 alone via the β-arrestin2/AKT pathway, whereas the heterodimer TAAR1/D2 inhibits GSK-3 via 
the same pathway, thus by inhibiting GSK-3, we expected GSK-3 inhibition to mimic TAAR1 activation effects. 
SB216763 was superfused at two different concentrations (0.1 and 1 μM), both alone and in the presence of 
cocaine. No effect was observed of either concentration of SB216763 on DA transmission when perfused alone 
(10.14 ± 9.59%, 10.12 ± 7.90% deviation from baseline peak and −5.59 ± 6.10%, 0.75 ± 3.25% deviation from 
baseline tau). ANOVA showed an effect of treatment on both cocaine-induced changes in peak DA (Fig. 5e; 
F(4,40) = 3.14, p = 0.024, n = 13) and tau (Fig. 5f; F(4,40) = 7.43, p = 0.001, n = 13). Post-hoc analyses showed that 
the lower concentration of SB216763 caused a significant increase in cocaine-induced DA release (87.90 ± 48.400; 
p < 0.01) and that cocaine effects on tau were dose-dependently attenuated by SB216763 (226.774 + 58.921 and 
35.199 + 16.004 respectively; p < 0.01).
Discussion
This study set out to examine the ability of TAAR1 to regulate the neurochemical effects of cocaine, measuring 
DA release and uptake dynamics in the NAc in real time. The results provided a straightforward demonstration 
Figure 4. Effects of PKC inhibition and activation on cocaine-induced changes in DA transmission. Co-
application of the lower concentrations of both PKC activator (PMA) and PKC inhibitor (Go 6983; Go) with 
cocaine (Co) resulted in a significant increase in peak DA (a). Both PMA and Go dose-dependently increased 
DA clearance in the presence of Co (b). Although 100 nM Go was without effect, there was a significant increase 
in DA peak compared to baseline values when perfused in combination with RO5256390. In the presence 
of 100 nM Go, RO5256390 still produced an attenuation of cocaine’s effect on tau (*p < 0.05, **p < 0.01 vs 
baseline; #p < 0.05, ##p < 0.01 vs cocaine values; n = 7–19).
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that TAAR1 activation completely prevented the effects of cocaine on DA uptake, which we showed to require 
co-activation of DA D2 autoreceptors, but not the recruitment of its associated PKA and PKC signalling cascades. 
Moreover, the data revealed that such cooperative interactions between TAAR1 and DA D2 receptors are likely 
to occur through inhibition of the β-arrestin2-dependent pathway, since GSK-3 inhibition fully reproduced the 
Figure 5. The DA D2 receptor antagonist, L-741,626, blocks RO5256390’s effects on cocaine-induced changes 
in DA transport. Co-application of cocaine (Co) with the DA D2 receptor antagonist, L-741,626 (L-741), dose-
dependently increased cocaine effects on DA release (a). This effect was also observed with the perfusion of the 
lower concentration of L-741 alone. Sumanirole (Suman), DA D2 receptor agonist dose-dependently produced 
a significant attenuation of cocaine’s effect on tau whereas L-741,626 significantly potentiated cocaine’s effect 
on tau (b). The lower concentration of L-741,626 (30 nM), which did not affect cocaine-induced changes in 
DA clearance when perfused with RO5256390 and cocaine, completely blocked RO5256390’s ability to inhibit 
cocaine’s effects on DA uptake (d). SB216763 (SB), a GSK-3 inhibitor, increased peak at the lower concentration 
(e) and significantly attenuated cocaine-induced DA increases in tau at the higher concentration (f). (*p < 0.05, 
**p < 0.01 vs baseline; #p < 0.05, ##p < 0.01 vs cocaine values; n = 5–19).
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effects of TAAR1 activation on cocaine-induced changes on DA clearance, though it increased DA release on 
co-application of cocaine. These findings uncover the primary mechanisms through which TAAR1 is able to 
regulate the alterations in DA transmission produced by cocaine (Fig. 6) and underscore the potential of TAAR1 
as a target for stimulant addiction treatment.
Cocaine is a psychomotor stimulant that exhibits rapid brain uptake and relatively short half-life (ca. 20 min), 
acting primarily by blocking the DAT, preventing DA reuptake and producing subsequent elevations of extracel-
lular levels of DA29. The characteristic pharmacokinetic profile of cocaine and the increases it produces in extra-
synaptic DA are believed to mediate its reinforcing and euphoric effects30,31. In addition, enhanced mesolimbic 
DA transmission is triggered by exposure to cocaine-related stimuli32 and coincides with the initiation of cocaine 
seeking behaviour33. Considerable experimental evidence indicates that DA transmission is strongly modulated 
by TAAR1. In patch clamp preparations, the full TAAR1 agonist, RO5256390, attenuated DA neuron firing in the 
ventral tegmental area6, whereas the partial agonist, RO5263397, augmented it under conditions of low neuronal 
discharge, as did the antagonist EPPTB8. These data suggests that TAAR1 is constitutively active and/or tonically 
activated by endogenous ligands, acting as a sentinel system to “normalise” DA neuron firing, which shifts bidi-
rectionally following cocaine exposure and withdrawal34,35. Intriguingly, both partial and full TAAR1 activation 
exhibit desirable behavioural effects in animal models of cocaine addiction. Our recent observations indicated 
that both partial and full TAAR1 agonists prevented the decreasing effects of cocaine on brain reward thresh-
olds11, produced a downward shift in the dose-response curve for cocaine self-administration11 and blocked the 
spontaneous renewal of cocaine seeking following chronic self-administration12. Additionally, neurochemical 
studies have recently shown that TAAR1 activation reduced DA overflow in the NAc induced by cocaine in vitro12 
and by methamphetamine both in vitro36 and in vivo37. Understanding the molecular mechanisms underlying this 
remarkable ability of TAAR1 to regulate the neurochemical and behavioural effects of psychomotor stimulants is 
a key step towards the development of more efficacious, TAAR1-based therapies for stimulant addiction.
Notwithstanding the extraordinary diversity of TAAR1 signalling mechanisms and the complexity of TAAR1 
molecular interactions, we used fast-scan cyclic voltammetry to measure DA fluctuations induced by cocaine in 
the NAc, studied the effects of full TAAR1 activation on cocaine’s neurochemical actions and explored the role 
played by the key TAAR1-associated biochemical cascades. In agreement with previous neurochemical studies12, 
we found here that TAAR1 activation prevented the effects of cocaine on DA transmission, at concentrations of 
cocaine that produced pronounced effects on DA uptake and no effects on release. When activated by TAs and 
other endogenous and exogenous ligands, TAAR1 increases cAMP in the presynaptic neuron via Gαs-protein 
activation of adenylyl cyclase which, in turn, promotes PKA and PKC phosphorylation. In heterologous expres-
sion systems both PKA and PKC phosphorylation can result in DAT internalization (i.e. noncompetitive reuptake 
inhibition)38,39, thus potentially elevating extracellular DA levels and preventing cocaine binding to the DAT. In 
addition, PKC activation can induce DAT function to reverse, leading to DA efflux38. In fact, TAAR1-dependent 
DA efflux has been attributed to TAAR1-mediated substrate phosphorylation40. These findings suggest that PKA/
PKC phosphorylation processes, most likely PKC, could be involved in TAAR1 regulation of cocaine’s effects on 
DA clearance.
At the doses tested we found that, unexpectedly, inhibition, but not activation, of PKA significantly 
increased peak DA concentrations, and that both activation and inhibition of this kinase increased DA release 
in the presence of cocaine. Although many downstream effectors are likely to be involved41, PKA stimulation 
Figure 6. Proposed mechanism of TAAR1’s role in modulating dopamine (DA) transmission fluctuations 
induced by cocaine. Cocaine blocks dopamine transporter (DAT) function and thus inhibits DA reuptake 
by binding to the DAT (1). The DA D2 receptor is a G-protein-coupled receptor, which, when attached to 
TAAR1 can form a heteromeric complex52. This complex potentiates DA D2 receptor-mediated pre-synaptic 
autoinhibition and inhibits DA D2 receptor-mediated post-synaptic signalling. As a sentinel system, TAAR1 
is sensitive to shifts in DA concentrations and promotes DA homeostasis (2). Sumanirole, a DA D2 receptor 
agonist causes a similar inhibition of cocaine-induced changes in DA uptake (3) and the antagonist L-741,626 
potentiates cocaine-induced effects on DA clearance (4). DA D2 receptor stimulation activates GSK-3 
β-arrestin2-dependent pathway (5) and the TAAR1/DA D2 receptor heteromeric complex inhibits GSK-3 
through the same pathway (6). Thus, inhibiting GSK-3 with SB631736 activates AKT, which is bound to D2/
DAT complex53, increasing DA reuptake (7).
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inactivates the small GTPase RhoA, which can prevent DAT internalization42 and possibly alter peak DA 
amplitude changes as well as uptake. PKA may also alter intracellular Ca2+ dynamics, increasing intracellular 
Ca2+ release, which may impact on DA release, likely via inhibiting the cAMP/PKA cascade after D2 receptor 
stimulation43. Moreover, we found that both activation and inhibition of PKA prevented the ability of cocaine 
to produce alterations in DA clearance suggesting that basal substrate phosphorylation at the DAT is required 
for cocaine to exert changes in DA transport and, similarly, that excessive PKA-mediated phosphorylation 
downregulates DAT function, which is in agreement with previous findings38. Importantly, PKA inhibition at 
a dose that was physiologically active (i.e. increasing DA release by itself) failed to alter the ability of TAAR1 
activation to block cocaine’s effects on tau, indicating that TAAR1 modulation of cocaine’s action is unlikely to 
be mediated by PKA.
Although multiple mechanisms have been linked to PKC-stimulated DAT endocytosis44, PKC activation with 
phorbol esters or Gq-coupled glutamate receptors stimulated DA efflux in slices of rat striatum45. At the doses we 
tested PKC stimulation did not enhance DA release when applied alone, but did in the presence of cocaine. As 
with PKA, both PKC activation and inhibition dose-dependently disrupted the ability of cocaine to prolong DA 
transmission. This suggests that basal substrate phosphorylation is essential but also that PKC-dependent endo-
cytic downregulation46, kinetic downregulation of DAT and alterations in DAT conformational equilibrium47, 
which is accompanied by decreased cocaine analogue affinity, may all underlie the reduced ability of cocaine to 
induce DA transport changes in the presence of PKC activation. Again, inhibition of PKC with Go 6983, at a dose 
that was neurochemically active (i.e. elevated DA release in the presence of RO5256390) did not prevent TAAR1 
activation from blocking cocaine’s effects on DA clearance, suggesting that PKC does not mediate TAAR1’s reg-
ulation of cocaine effects.
Strong evidence implicates DA D2 autoreceptors in the release and uptake of DA during neurotransmission48 
and in the neurochemical effects of cocaine. For example, deletion of DA D2 autoreceptors amplified the actions 
of cocaine on DA transmission in the NAc49. Our observations were consistent with these findings since the 
DA D2 agonist, sumanirole, decreased the effects of cocaine on DA uptake whereas the antagonist, L-741,626, 
dose-dependently increased DA release and tau following cocaine treatment. Importantly, L-741,626, at a dose 
that did not alter cocaine effects on clearance but mildly elevated cocaine effects on release, fully rescued the 
ability of cocaine to elevate DA transmission in the presence of full TAAR1 activation. These data demonstrate 
that TAAR1 and DA D2 receptors act cooperatively to suppress cocaine’s neurochemical actions. In support of 
this hypothesis, previous data have shown that in heterologous expressing systems, the presence of DA D2 recep-
tors decreased TAAR1-mediated cAMP signalling while enhancing TAAR1-suppressing effects on GSK-317. 
We therefore predicted that GSK-3 inhibition with SB216763 would reproduce the effects of full TAAR1 acti-
vation on cocaine’s actions on DA transmission. This prediction was confirmed fully, thus suggesting that 
TAAR1/DA D2 receptor interactions critically regulate cocaine’s neurochemical actions through silencing of the 
β-arrestin2-AKT-GSK-3 pathway. This is consistent with an emerging role of GSK-3 in mediating key behavioural 
actions of cocaine, such as sensitization50 and conditioned reward51. It must be noted however, that although 
GSK-3 inhibition did mimic the effects of TAAR1 activation, both when applied alone and/or in combination 
with cocaine, we acknowledge that GSK-3 is involved in several signalling pathways which could operate inde-
pendently of TAAR1. Future experiments may thus look at selective GSK-3 activation in this model, which we 
would predict would prevent the effects of TAAR1 on cocaine as seen here with the D2 antagonist. No selective 
activator of GSK-3 is currently available.
In summary, the present study demonstrated the ability of full TAAR1 activation to modulate DA transmis-
sion and prevent cocaine-induced changes on DA neurotransmission. Furthermore, these findings also identified 
the likely molecular mechanisms through which TAAR1 exerts such remarkable effects, thus uncovering a novel 
strategy to disrupt cocaine’s actions in the brain. Indeed, TAAR1/DA D2 receptor interactions, and their down-
stream signalling pathways converging on GSK-3, may provide alternative targets for the development of new 
treatments not only for stimulant addiction but also for other disorders involving DA dysfunction, including 
schizophrenia and bipolar disorder.
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